Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Special Drug Use-results Survey to Evaluate the Safety and Efficacy of Subcutaneous Administration of Cosentyx in Pediatric Patients With Psoriasis Vulgaris, Psoriatic Arthritis, or Pustular Psoriasis

NCT05215561 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT05215561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05215561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Special Drug Use-results Survey to Evaluate the Safety and Efficacy of Subcutaneous Administration of Cosentyx in Pediatric Patients With Psoriasis Vulgaris, Psoriatic Arthritis, or Pustular Psoriasis
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
February 14, 2022
Completion date
September 28, 2024
Enrollment
36 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis vulgaris, psoriatic arthritis, pustular psoriasis